pan>)--Atherotech Diagnostics Lab has announced two new executive position
hires. Joseph Chimera, Ph.D., has been named executive vice president of
scientific development and J. Georges Nitis, Ph.D., M.B.A., has been
appointed as vice president of laboratory operations.
“Their
scientific leadership enhances Atherotechs infrastructure and will
support our explosive growth and increased demand for our clinical
laboratory services.”
Both Dr. Chimera and Dr. Nitis bring a wealth of talent and industry
expertise to our team, said Michael Mullen, CEO of Atherotech. Their
scientific leadership enhances Atherotechs infrastructure and will
support our explosive growth and increased demand for our clinical
laboratory services.
As executive vice president of scientific development, Chimera will lead
the overall scientific initiatives at Atherotech Diagnostics Lab.
Chimera has over 25 years of experience leading profitable growth
strategies in the CLIA-certified and contract research laboratory
marketplace. His background includes: new product development,
negotiating service agreements, market expansion and operation of
several types of laboratories, including physician office labs, CLIA
reference labs, and occupational and forensic labs.
Chimera has served in various high-profile roles throughout his career,
including general manager, laboratory director and senior vice president
of business development. Prior to this, he was employed for more than 10
years at LabCorp, where he served as general manager of clinical trials
lab division, assistant vice president of molecular diagnostics and
national director of molecular diagnostics.
J. Georges Nitis comes to Atherotech with more than 35 years of
progressive laboratory experience and expertise in administrative
laboratory functions, technical operations, regulatory affairs and
quality assurance. Nitis will be responsible for strengthening
Atherotechs infrastructure to support the companys growth and
expansion.
Nitis started his career at Dow Chemical Bio-Science Laboratories and
went on to work in progressively increasing areas of responsibility at
International Clinical Laboratories, Microbiological Associates Inc.,
Quest Clinical Labs and Binax Inc. He also co-founded Neorx Corporation,
a biotechnology company that developed cancer diagnostic and therapeutic
products. Most recently, Nitis served as administrative laboratory
director at Maine General Medical Center in Augusta, Maine, and Fremont
Area Medical Center in Fremont, Neb.
Atherotechs patented VAP Test identifies a significantly greater number
of people at risk for heart disease than the standard cholesterol test,
with direct and comprehensive measurements of cholesterol markers
associated with heart disease. Atherotech Diagnostics Lab provides
physicians with a single source for the VAP Test and more than 50
cardiovascular and metabolic tests. The company provides its unique
testing services to physicians, hospitals, clinics and other
laboratories throughout the U.S.
For information visit www.Atherotech.com
or call 877.901.8510. Atherotech Diagnostics Lab is on Twitter at www.Twitter.com/Atherotech
and also on Facebook at www.Facebook.com/Atherotech.
About Atherotech Diagnostics Lab
Atherotech is a CLIA-certified clinical reference laboratory and
cardiodiagnostic company focusing on cardiometabolic tests, including
the companys patented VAP Cholesterol Test, which reports the
cholesterol content of all lipids, components and subclasses. The VAP
Test is the first cholesterol profile to comply with updated National
Cholesterol Education Program ATP III recommendations for direct LDL
measurement, which is accurate with non-fasting samples. The VAP Test is
available through national and regional diagnostic laboratories and is
reimbursed by many of the largest private insurers as well as Medicare.
For more information, visit www.Atherotech.com.
Information Source: Business Wire
